Legal & General Group Plc Takes $1.48 Million Position in Trevi Therapeutics, Inc. $TRVI

Legal & General Group Plc bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 79,220 shares of the company’s stock, valued at approximately $1,477,000. Legal & General Group Plc owned 0.06% of Trevi Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of TRVI. Hilton Head Capital Partners LLC raised its holdings in shares of Trevi Therapeutics by 32.6% during the first quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock valued at $51,000 after purchasing an additional 1,044 shares during the period. AlphaCentric Advisors LLC boosted its holdings in Trevi Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock worth $286,000 after acquiring an additional 1,303 shares in the last quarter. Kennedy Capital Management LLC grew its stake in Trevi Therapeutics by 2.4% in the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after acquiring an additional 1,336 shares during the period. California State Teachers Retirement System grew its stake in Trevi Therapeutics by 2.6% in the fourth quarter. California State Teachers Retirement System now owns 83,788 shares of the company’s stock valued at $1,049,000 after acquiring an additional 2,091 shares during the period. Finally, KBC Group NV bought a new stake in shares of Trevi Therapeutics during the first quarter valued at approximately $29,000. 95.76% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TRVI. Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. B. Riley Financial increased their price target on Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Raymond James Financial restated a “strong-buy” rating and set a $40.00 price objective on shares of Trevi Therapeutics in a research note on Friday, August 7th. Oppenheimer upped their target price on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Trevi Therapeutics in a report on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $27.08.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $17.26 on Monday. Trevi Therapeutics, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $20.22. The business has a 50-day moving average of $17.96 and a 200 day moving average of $15.01. The firm has a market cap of $2.46 billion, a P/E ratio of -50.76 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). As a group, research analysts predict that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.